Unlocking the future of medicine
A primary goal of personalized medicine is to provide the best medical treatment for each individual patient by determining which drug will have the best efficacy and have the least amount of toxicity and/or adverse effects. Furthermore, understanding interindividual variations of response to drug treatment, especially in patients with potential adverse reactions, might lead to biomarkers that can be used to predict the low incidence of idiosyncratic toxicity. Individualized medicine is usually based on the concept of pharmacogenomics that studies the influence of an individual’s genotype and/or SNPs on their response to a drug or medical treatment.
When drugs are prescribed, personalized medicine will use metabolic validation testing to predict how individuals will metabolize the compound. One example of this pharmacogenomics approach is the FDA approval of genetic tests that can predict the appropriate starting dose of the blood thinner warfarin (trade name Coumadin).
Because warfarin has a very narrow therapeutic range and because there is high inter- and intra-patient variability in response, finding the optimal dose can be challenging. While there are non-genetic factors that affect individual response, it is known that variations in two specific genes are associated with response to warfarin, and it has been suggested that pharmacogenomic-based dosing could speed up the determination of the appropriate initial therapeutic dose.
Medical School and Pharmacogenomics
Pharmacogenomics has been the major focus area to date; 84% of medical schools in the United Kingdom and 74% of U.S. and Canadian medical schools include pharmacogenomics in their curricula.
Source: Medscape.com
PGx Medical
Individualized Care – Personalized Medicine
405-509-5112
info@pgxmed.com